Kyverna Therapeutics

EMERYVILLE, CA · Biotech · Public

anti-CD19 CAR-T cell therapy for autoimmune diseases

Claim this profile

Follows are private to you and power your alerts

Updated · kyvernatx.com

Sector
Biotech
Headquarters
EMERYVILLE, CA
Latest Form D
$152M, Nov 2023
Total capital
$152M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$152M
1 Form D · last Nov 2023
36 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
38 pending · first 2022
Rank in peer group#397 of 1449

Capital timeline

2023FEDERAL ↑EQUITY ↓Cumulative $152M1st Form D$152M
2023FEDERAL ↑EQUITY ↓Cumulative $152M1st Form D$152M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$152M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#397 · top 27%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Beth SpiegelmanDirectorNamed in SEC Form D filings
  • Brian KotzinDirectorNamed in SEC Form D filings
  • Dan SpiegelmanDirectorNamed in SEC Form D filings
  • Dominic BorieExecutive OfficerNamed in SEC Form D filings
  • Fred CohenDirectorNamed in SEC Form D filings
  • Ian ClarkDirectorNamed in SEC Form D filings
Show all 11 people
  • James ChungExecutive OfficerNamed in SEC Form D filings
  • Karen WalkerExecutive OfficerNamed in SEC Form D filings
  • Peter MaagExecutive Officer, DirectorNamed in SEC Form D filings
  • Ryan JonesExecutive OfficerNamed in SEC Form D filings
  • Steve LiapisDirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 40
  • PendingMethods For Treating Autoimmune DiseasesUSPTOApplication 19402188
  • PendingMethods For Treating Stiff Person Syndrome And Myasthenia Gravis Using ANTI-CD19 Car-t Cell TherapeuticsUSPTOApplication 18827646
  • PendingMethods Of Treating Lupus Nephritis Using ANTI-CD19 Car-t Cell TherapiesUSPTOApplication 18827623
Show all 40 patent records
  • Methods For Treating Autoimmune DiseasesMay 21, 2026 · Application 19402188Pending
  • Methods For Treating Stiff Person Syndrome And Myasthenia Gravis Using ANTI-CD19 Car-t Cell TherapeuticsJan 30, 2025 · Application 18827646Pending
  • Methods Of Treating Lupus Nephritis Using ANTI-CD19 Car-t Cell TherapiesDec 26, 2024 · Application 18827623Pending
  • Methods And Compositions For Treating Autoimmune DiseaseAug 8, 2024 · Application 18329959Pending
  • Methods For Increasing T-cell FunctionMay 16, 2024 · Application 18417170Pending
  • Methods For Increasing T-cell FunctionJan 23, 2024 · US 11,879,003Granted
  • Methods And Compositions For Treating Autoimmune DiseaseDec 14, 2023 · Application 18300919Pending
  • Methods Of Producing T Regulatory Cells, Methods Of Transducing T Cells, And Uses Of The SameOct 19, 2023 · Application 17985587Pending
  • Methods For Treating Autoimmune DiseasesJul 6, 2023 · Application 17984814Pending
  • A Method For Treating Disease Using FOXP3+CD4+ T CellsApr 6, 2023 · Application 17979437Pending
  • Methods And Compositions For Treating Disease Using Targeted FOXP3+CD4+ T Cells And Cellular Suicide AgentsFeb 23, 2023 · Application 17721927Pending
  • A Method For Treating Disease Using FOXP3+CD4+ T CellsSep 20, 2022 · US 11,446,357Granted
  • Method For Treating Disease Using FOXP3+CD4+ T CellsJun 2, 2022 · Application 17523431Pending
  • Method For Treating Disease Using FOXP3+CD4+ T CellsApr 14, 2022 · Application 17499157Pending
  • Methods Of Producing T Regulatory Cells, Methods Of Transducing T Cells, And Uses Of The SameFeb 3, 2022 · Application 17391767Pending
  • Methods For Treating Myasthenia Gravis Using ANTI-CD19 Car-t Cell TherapiesApplication 63620673Pending
  • Allogeneic Car-t Cell Therapies And Manufacture ThereofApplication 63620643Pending
  • Methods For Treating Systemic Sclerosis Using ANTI-CD19 Car-t Cell TherapiesApplication 63597233Pending
  • Methods For Treating Myasthenia Gravis Using ANTI-CD19 Car-t Cell TherapiesApplication 63596770Pending
  • Methods For Treating Myasthenia Gravis Using ANTI-CD19 Car-t Cell TherapiesApplication 63596951Pending
  • Methods For Manufacture Of Engineered T Cells From Whole Blood SamplesApplication 63547255Pending
  • Methods For Treating Multiple Sclerosis Using ANTI-CD19 Car-t Cell TherapiesApplication 63594837Pending
  • Methods For Treating Lupus Nephritis Using ANTI-CD19 Car-t Cell TherapiesApplication PCTUS2023077760Pending
  • Methods For Treating Systemic Sclerosis Using ANTI-CD19 Car-t Cell TherapiesApplication 63589588Pending
  • Methods For Treating Systemic Sclerosis Using ANTI-CD19 Car-t Cell TherapiesApplication 63587991Pending
  • Methods For Treating Lupus Nephritis Using ANTI-CD19 Car-t Cell TherapiesApplication 63587329Pending
  • Allogeneic Car-t Cell Therapies And Manufacture ThereofApplication 63579076Pending
  • Methods For Treating Lupus Nephritis Using ANTI-CD19 Car-t Cell TherapiesApplication 63518745Pending
  • Methods For Rapid Manufacture Of Engineered T Cells Expressing Chimeric Antigen ReceptorsApplication 63518503Pending
  • Methods For Treating Myasthenia Gravis Using ANTI-CD19 Car-t Cell TherapiesApplication 63516378Pending
  • Methods For Rapid Manufacture Of Engineered T Cells Expressing Chimeric Antigen ReceptorsApplication 63515025Pending
  • Methods Of Treating Lupus Nephritis Using ANTI-CD19 Car-t Cell TherapiesApplication 63512061Pending
  • Methods And Compositions For Treating Autoimmune DiseaseApplication PCTUS2023067972Pending
  • Methods And Compositions For Treating Autoimmune DiseaseApplication PCTUS2023065782Pending
  • Methods For Treating Autoimmune DiseasesApplication PCTUS2023010034Pending
  • Methods For Treating Autoimmune DiseasesApplication 63419193Pending
  • Methods And Compositions For Treating Autoimmune DiseaseApplication 63350141Pending
  • Methods And Compositions For Treating Disease Using Targeted FOXP3+CD4+ T Cells And Cellular Suicide AgentsApplication PCTUS2022025033Pending
  • Methods And Compositions For Treating Autoimmune DiseaseApplication 63331397Pending
  • Methods Of Producing Regulatory T Cells And Use Of The SameApplication PCTUS2022018324Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .